Last reviewed · How we verify
inhaled corticosteroid
The inhaled corticosteroid developed by the University of Alberta is currently marketed, positioning it as an established player in the respiratory therapy segment. A key strength is the protection afforded by the key composition patent, which does not expire until 2028, providing a strong barrier to generic competition. The primary risk is the lack of disclosed revenue data, which may indicate limited commercial success or market penetration.
At a glance
| Generic name | inhaled corticosteroid |
|---|---|
| Also known as | Flovent; Pulmicort; Alvesco., Inhaled fluticasone propionate |
| Sponsor | University of Alberta |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.
- Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma (PHASE2)
- Hydroxychloroquin (HCQ) in chILD of Genetic Defect (NA)
- Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment (PHASE3)
- A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation (PHASE4)
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- inhaled corticosteroid CI brief — competitive landscape report
- inhaled corticosteroid updates RSS · CI watch RSS
- University of Alberta portfolio CI